title: Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.
abstract: OBJECTIVE
  A network meta-analysis was performed to compare the short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer.
  
  
  METHODS
  Randomized controlled trials of different chemotherapy regimens for advanced gastric cancer were included in this study. Network meta-analysis combined direct evidence and indirect evidence to evaluate the odds ratio and draw surface under the cumulative ranking curves of different chemotherapy regimens in advanced gastric cancer.
  
  
  RESULTS
  The results of surface under the cumulative ranking curves showed that S-1 and capecitabine regimens were better than fluorouracil. As for multi-drug combination regimens, the disease control rate of cisplatin + capecitabine, docetaxel + cisplatin + fluorouracil and etoposide + cisplatin + capecitabine regimens were relatively better, while fluorouracil + adriamycin + mitomycin regimen was relatively poorer when compared with cisplatin + fluorouracil regimen. Additionally, the overall response ratio of cisplatin + capecitabine, paclitaxel + fluorouracil, docetaxel + cisplatin + fluorouracil and etoposide + cisplatin + fluorouracil regimens were relatively better, while the disease control rate of fluorouracil + adriamycin + mitomycin regimen was relatively poorer when compared with cisplatin + fluorouracil regimen. Furthermore, the results of cluster analysis demonstrated that cisplatin + capecitabine, etoposide + cisplatin + capecitabine, S-1 + paclitaxel and S-1 + irinotecan chemotherapy regimens had better disease control rate and overall response ratio for advanced gastric cancer patients.
  
  
  CONCLUSIONS
  This network meta-analysis clearly showed that multi-drug combination chemotherapy regimens based on capecitabine and S-1 might be the best chemotherapy regimen for advanced gastric cancer.
authors.affiliation: Department of Medicine, Shigatse People's Hospital, Shigatse 857000, P.R. China.
authors.forename: Mi-Ma
authors.initials: MM
authors.lastname: Duo-Ji
authors.affiliation: Department of Medicine, Shigatse People's Hospital, Shigatse 857000, P.R. China.
authors.forename: Ba-Sang
authors.initials: BS
authors.lastname: Ci-Ren
authors.affiliation: Department of Gastric Cancer and Soft-Tissue Sarcoma Sugery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.
authors.forename: Zi-Wen
authors.initials: ZW
authors.lastname: Long
authors.affiliation: Department of Medicine, Shigatse People's Hospital, Shigatse 857000, P.R. China.
authors.forename: Xiao-Hua
authors.initials: XH
authors.lastname: Zhang
authors.affiliation: Department of Medicine, Shigatse People's Hospital, Shigatse 857000, P.R. China.
authors.forename: Dong-Lin
authors.initials: DL
authors.lastname: Luo
mesh_terms: D000069287:Capecitabine / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D005472:Fluorouracil / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010094:Oxonic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000069287:Capecitabine; D005472:Fluorouracil
keywords: S-1; capecitabine; chemotherapy; fluorouracil; gastric cancer